MBC Research, Inc.

AURORA, CO 80045

SBIR Award Summary

Total Number of Awards 14
Total Value of Awards $5.08MM
Active Awards 2 valued at $1.44MM
First Award Date 09/06/02
Most Recent Award Date 09/12/17

2 Active Awards Valued at $1.44MM

Award Title Awarding Agency Phase Award amount Start Date End Date
Novel Bone-Targeting Combination Therapy for Osteosarcoma Phase II HHS 2 $1.14MM 09/12/17 08/31/18
Bone Targeted Antibiotics HHS 1 $300K 08/07/17 07/31/18

Key Personnel

Last Name Name Awards Contact
Reinholz Monica Madden Reinholz 2
Hefferan Theresa E Hefferan 1
Karpeisky Alexander Karpeisky 6 Message
Zinnen Shawn Patrick Zinnen 5
THAMM DOUGLAS H THAMM 1

14 Awards Won

Phase 2 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 09/12/17 - 08/31/18

Project Summary/Abstract: The overall aim of this project is to further develop a novel gemcitabine-ibandronate conjugate alone and/or as part of a combination therapy for the treatment of osteosarcoma and associated metastases. The conjugate consists of chemically linked anticancer antimetabolite Gemcitabine and the bone-homing bisphosphonate I...

Phase 1 SBIR Active

Agency: Department of Health & Human Services
Topic: PA-16-302
Budget: 08/07/17 - 07/31/18

Project Summary/Abstract: The overall goal of this project is to develop novel bone-targeted conjugates of clinically relevant antibiotics for the treatment of osteomyelitis. These compounds are new chemical entities built from known and approved antibiotics and bisphosphonates, which are connected via biodegradable phosphate linker. The design ...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-14-071
Budget: 02/01/16 - 01/31/17

? DESCRIPTION (provided by applicant): The overall aim of this project is to evaluate the feasibility of using a novel gemcitabine-ibandronate conjugate alone and/or as part of a combination therapy for the treatment of osteosarcoma and associated metastases. The conjugate consists of chemically linked anticancer antimetabolite Gemcitabine an...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 06/01/13 - 05/31/14

DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form th...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic: PA-12-088
Budget: 06/01/13 - 05/31/15

DESCRIPTION (provided by applicant): The long-term goal of this proposal is to develop more effective therapies for cancer, specifically pancreatic cancer. The specific focus of this proposal is to improve upon the anti-cancer activity of the drug gemcytabine. This will be accomplished by synthesizing novel conjugates of gemcytabine in a form th...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 08/01/11 - 07/31/13

DESCRIPTION (provided by applicant): The goal of this project is to further develop novel bisphosphonate conjugate MBC-11 and other novel compounds as treatment for prostate cancer (PC) and PC-induced bone disease. MBC-11 is the anhydride formed between arabinocytidine (AraC)-59-phosphate and etidronate and is the lead product of our proprietary...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 08/01/11 - 07/31/14

DESCRIPTION (provided by applicant): The goal of this project is to further develop novel bisphosphonate conjugate MBC-11 and other novel compounds as treatment for prostate cancer (PC) and PC-induced bone disease. MBC-11 is the anhydride formed between arabinocytidine (AraC)-59-phosphate and etidronate and is the lead product of our proprietary...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-09-080
Budget: 08/15/10 - 07/31/11

DESCRIPTION (provided by applicant): The goal of this project is to further develop novel bisphosphonate conjugate MBC-11 and other novel compounds as treatment for prostate cancer (PC) and PC-induced bone disease. MBC-11 is the anhydride formed between arabinocytidine (AraC)-59-phosphate and etidronate and is the lead product of our proprietary...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-280
Budget: 09/01/09 - 08/31/11

DESCRIPTION (provided by applicant): The overall goal of this project is to further develop novel bisphosphonate conjugate MBC-11 as treatment for tumor-induced bone diseases such as those associated with multiple myeloma. MBC-11 is the anhydride formed between arabinocytidine (AraC)-5'-phosphate and etidronate and is the lead product of our pro...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic: PA-07-80
Budget: 09/22/08 - 08/31/09

DESCRIPTION (provided by applicant): The overall goal of this project is to further develop novel bisphosphonate conjugate MBC-11 as treatment for tumor-induced bone diseases such as those associated with multiple myeloma. MBC-11 is the anhydride formed between arabinocytidine (AraC)-5'-phosphate and etidronate and is the lead product of our pro...

Load More